Rukobia (Fostemsavir Tromethamine) Patent Expiration, LOE Window & CMS Spending
Rukobia (Fostemsavir Tromethamine) by GSK: FDA Orange Book core substance LOE 2027-11-19 (last listed 2029-07-13), 0 AB generics, $138.3M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | GSK |
| FDA Application & Pathway | N212950 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2027-11-19 |
| Last Listed Patent or Exclusivity Date | 2029-07-13 |
| Orange Book Patents (*PED Extensions) | 2 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $138.3M |
| 2024 Medicare Part D Spend | $115.0M |
| 2024 Medicaid Spend | $23.2M |
| Reported Wholesale Price Change (CA SB 17) | 1 WAC filings (max 17.8% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.